오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 45.71 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: sodium lauryl sulfate; indigo carmine; titanium dioxide; gelatin; pregelatinised maize starch; dimeticone 350; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 28.57 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; dimeticone 350; gelatin; indigo carmine; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 20.57 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; sodium lauryl sulfate; dimeticone 350; titanium dioxide; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; gelatin; sodium lauryl sulfate; dimeticone 350; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 483 mg (equivalent: olanzapine, qty 210 mg) - diluent, not applicable - excipient ingredients: carmellose sodium; mannitol; hydrochloric acid; polysorbate 80; sodium hydroxide; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 690 mg (equivalent: olanzapine, qty 300 mg) - diluent, not applicable - excipient ingredients: hydrochloric acid; polysorbate 80; carmellose sodium; mannitol; sodium hydroxide; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 931 mg (equivalent: olanzapine, qty 405 mg) - diluent, not applicable - excipient ingredients: hydrochloric acid; carmellose sodium; sodium hydroxide; mannitol; polysorbate 80; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 20 mg - wafer - excipient ingredients: aspartame; sodium propyl hydroxybenzoate; gelatin; sodium methyl hydroxybenzoate; mannitol - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 15 mg - wafer - excipient ingredients: aspartame; mannitol; gelatin; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 10 mg - wafer - excipient ingredients: sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; gelatin; mannitol; aspartame - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.